Genzyme pays Biosurgery shareholders
This article was originally published in The Gray Sheet
Executive Summary
Genzyme Biosurgery shareholders receive $64 million settlement in class action lawsuit against parent Genzyme Corp. dating back to a May 8, 2003, forced buyback of shares at 32% below market price. The settlement nearly doubles the value of the original payout, attorneys say in a Jan. 13 statement